For the quarter ending 2025-09-30, CADL made $13,014K in revenue. -$11,269K in net income. Net profit margin of -86.59%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 8,461 | 6,991 | ||
| General and administrative | 4,746 | 4,186 | ||
| Total operating expenses | 13,207 | 11,177 | ||
| Loss from operations | -13,207 | -11,177 | ||
| Interest income | 953 | 926 | ||
| Interest expense | 161 | 236 | ||
| Change in fair value of warrant liability | -1,146 | -5,691 | ||
| Total other income (expense), net | 1,938 | 6,381 | ||
| Net loss and comprehensive loss | -11,269 | -4,796 | ||
| Earnings per share, basic | -0.21 | -0.09 | ||
| Earnings per share, diluted | -0.21 | -0.09 | ||
| Weighted average number of shares outstanding, basic | 54,894,347 | 51,489,929 | ||
| Weighted average number of shares outstanding, diluted | 54,894,347 | 51,489,929 | ||
Candel Therapeutics, Inc. (CADL)
Candel Therapeutics, Inc. (CADL)